JP7273803B2 - 特定のコントラスト機構を用いて構造的空間周波数を評価するための選択的サンプリング - Google Patents
特定のコントラスト機構を用いて構造的空間周波数を評価するための選択的サンプリング Download PDFInfo
- Publication number
- JP7273803B2 JP7273803B2 JP2020516380A JP2020516380A JP7273803B2 JP 7273803 B2 JP7273803 B2 JP 7273803B2 JP 2020516380 A JP2020516380 A JP 2020516380A JP 2020516380 A JP2020516380 A JP 2020516380A JP 7273803 B2 JP7273803 B2 JP 7273803B2
- Authority
- JP
- Japan
- Prior art keywords
- signal
- value
- texture
- contrast
- values
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000007246 mechanism Effects 0.000 title claims description 45
- 238000005070 sampling Methods 0.000 title description 83
- 238000005259 measurement Methods 0.000 claims description 290
- 238000000034 method Methods 0.000 claims description 241
- 238000003384 imaging method Methods 0.000 claims description 129
- 238000009792 diffusion process Methods 0.000 claims description 101
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 45
- 238000002597 diffusion-weighted imaging Methods 0.000 claims description 36
- 230000005284 excitation Effects 0.000 claims description 30
- 238000002598 diffusion tensor imaging Methods 0.000 claims description 27
- 238000012935 Averaging Methods 0.000 claims description 24
- 230000008569 process Effects 0.000 claims description 23
- 238000012045 magnetic resonance elastography Methods 0.000 claims description 15
- 230000005415 magnetization Effects 0.000 claims description 13
- 238000012805 post-processing Methods 0.000 claims description 10
- 238000012546 transfer Methods 0.000 claims description 9
- 238000004611 spectroscopical analysis Methods 0.000 claims description 5
- 230000008878 coupling Effects 0.000 claims description 4
- 238000010168 coupling process Methods 0.000 claims description 4
- 238000005859 coupling reaction Methods 0.000 claims description 4
- 230000000977 initiatory effect Effects 0.000 claims 6
- 210000001519 tissue Anatomy 0.000 description 258
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 175
- 201000010099 disease Diseases 0.000 description 174
- 230000033001 locomotion Effects 0.000 description 118
- 230000007170 pathology Effects 0.000 description 103
- 210000000988 bone and bone Anatomy 0.000 description 84
- 206010028980 Neoplasm Diseases 0.000 description 80
- 238000002595 magnetic resonance imaging Methods 0.000 description 71
- 239000000523 sample Substances 0.000 description 63
- 210000004556 brain Anatomy 0.000 description 61
- 238000010801 machine learning Methods 0.000 description 55
- 238000001574 biopsy Methods 0.000 description 49
- 230000006870 function Effects 0.000 description 49
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 48
- 238000003745 diagnosis Methods 0.000 description 46
- 206010016654 Fibrosis Diseases 0.000 description 45
- 230000003902 lesion Effects 0.000 description 45
- 210000000056 organ Anatomy 0.000 description 43
- 230000004761 fibrosis Effects 0.000 description 42
- 230000004044 response Effects 0.000 description 42
- 208000024827 Alzheimer disease Diseases 0.000 description 40
- 206010061818 Disease progression Diseases 0.000 description 37
- 201000006417 multiple sclerosis Diseases 0.000 description 36
- 238000011161 development Methods 0.000 description 35
- 230000018109 developmental process Effects 0.000 description 35
- 230000005750 disease progression Effects 0.000 description 35
- 238000009826 distribution Methods 0.000 description 35
- 230000000694 effects Effects 0.000 description 35
- 210000005166 vasculature Anatomy 0.000 description 34
- 238000004422 calculation algorithm Methods 0.000 description 33
- 206010012289 Dementia Diseases 0.000 description 30
- 239000000090 biomarker Substances 0.000 description 30
- 230000001054 cortical effect Effects 0.000 description 28
- 230000001965 increasing effect Effects 0.000 description 28
- 210000004185 liver Anatomy 0.000 description 28
- 210000004369 blood Anatomy 0.000 description 24
- 239000008280 blood Substances 0.000 description 24
- 238000001228 spectrum Methods 0.000 description 24
- 230000000875 corresponding effect Effects 0.000 description 23
- 239000003550 marker Substances 0.000 description 23
- 238000011282 treatment Methods 0.000 description 23
- 208000019423 liver disease Diseases 0.000 description 22
- 210000004072 lung Anatomy 0.000 description 21
- 238000002560 therapeutic procedure Methods 0.000 description 21
- 206010017076 Fracture Diseases 0.000 description 20
- 102000006386 Myelin Proteins Human genes 0.000 description 20
- 108010083674 Myelin Proteins Proteins 0.000 description 20
- 230000002596 correlated effect Effects 0.000 description 20
- 230000003176 fibrotic effect Effects 0.000 description 20
- 210000005012 myelin Anatomy 0.000 description 20
- 208000010392 Bone Fractures Diseases 0.000 description 19
- 230000008859 change Effects 0.000 description 19
- 238000002592 echocardiography Methods 0.000 description 19
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 18
- 230000007423 decrease Effects 0.000 description 18
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 18
- 210000002307 prostate Anatomy 0.000 description 18
- 230000035945 sensitivity Effects 0.000 description 18
- 239000000126 substance Substances 0.000 description 18
- 210000004885 white matter Anatomy 0.000 description 18
- 238000002591 computed tomography Methods 0.000 description 17
- 238000012544 monitoring process Methods 0.000 description 17
- 230000010412 perfusion Effects 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 206010061218 Inflammation Diseases 0.000 description 15
- 230000037180 bone health Effects 0.000 description 15
- 210000001320 hippocampus Anatomy 0.000 description 15
- 238000001727 in vivo Methods 0.000 description 15
- 230000004054 inflammatory process Effects 0.000 description 15
- 230000015556 catabolic process Effects 0.000 description 14
- 238000012512 characterization method Methods 0.000 description 14
- 238000013507 mapping Methods 0.000 description 14
- 230000036961 partial effect Effects 0.000 description 14
- 208000024891 symptom Diseases 0.000 description 14
- 210000004204 blood vessel Anatomy 0.000 description 13
- 239000002872 contrast media Substances 0.000 description 13
- 230000006378 damage Effects 0.000 description 13
- 238000010586 diagram Methods 0.000 description 13
- 238000011156 evaluation Methods 0.000 description 13
- 239000002207 metabolite Substances 0.000 description 13
- 230000001537 neural effect Effects 0.000 description 13
- 102000008186 Collagen Human genes 0.000 description 12
- 108010035532 Collagen Proteins 0.000 description 12
- 210000003484 anatomy Anatomy 0.000 description 12
- 229920001436 collagen Polymers 0.000 description 12
- 238000006731 degradation reaction Methods 0.000 description 12
- 238000000605 extraction Methods 0.000 description 12
- 230000010363 phase shift Effects 0.000 description 12
- 230000009467 reduction Effects 0.000 description 12
- 230000036962 time dependent Effects 0.000 description 12
- 230000002792 vascular Effects 0.000 description 12
- 208000016192 Demyelinating disease Diseases 0.000 description 11
- 206010012305 Demyelination Diseases 0.000 description 11
- 238000005481 NMR spectroscopy Methods 0.000 description 11
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 11
- 230000033115 angiogenesis Effects 0.000 description 11
- 238000013459 approach Methods 0.000 description 11
- 230000003376 axonal effect Effects 0.000 description 11
- 230000008901 benefit Effects 0.000 description 11
- 201000011510 cancer Diseases 0.000 description 11
- 208000026106 cerebrovascular disease Diseases 0.000 description 11
- 230000036541 health Effects 0.000 description 11
- 230000006872 improvement Effects 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 206010003805 Autism Diseases 0.000 description 10
- 208000020706 Autistic disease Diseases 0.000 description 10
- 208000012902 Nervous system disease Diseases 0.000 description 10
- 208000025966 Neurological disease Diseases 0.000 description 10
- 206010060862 Prostate cancer Diseases 0.000 description 10
- 208000010877 cognitive disease Diseases 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 230000009021 linear effect Effects 0.000 description 10
- 230000004807 localization Effects 0.000 description 10
- 230000001575 pathological effect Effects 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 230000000982 vasogenic effect Effects 0.000 description 10
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 9
- 208000019693 Lung disease Diseases 0.000 description 9
- 206010030113 Oedema Diseases 0.000 description 9
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 9
- 210000005013 brain tissue Anatomy 0.000 description 9
- 230000009787 cardiac fibrosis Effects 0.000 description 9
- 230000001413 cellular effect Effects 0.000 description 9
- 210000003710 cerebral cortex Anatomy 0.000 description 9
- 208000019425 cirrhosis of liver Diseases 0.000 description 9
- 230000001149 cognitive effect Effects 0.000 description 9
- 238000012937 correction Methods 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 9
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 9
- 230000003562 morphometric effect Effects 0.000 description 9
- 238000013425 morphometry Methods 0.000 description 9
- 210000002569 neuron Anatomy 0.000 description 9
- 230000008520 organization Effects 0.000 description 9
- 238000012545 processing Methods 0.000 description 9
- 238000004088 simulation Methods 0.000 description 9
- 230000003595 spectral effect Effects 0.000 description 9
- 230000002123 temporal effect Effects 0.000 description 9
- 229910052688 Gadolinium Inorganic materials 0.000 description 8
- 230000002159 abnormal effect Effects 0.000 description 8
- 230000007850 degeneration Effects 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 8
- 230000006866 deterioration Effects 0.000 description 8
- 238000006073 displacement reaction Methods 0.000 description 8
- 210000001353 entorhinal cortex Anatomy 0.000 description 8
- 239000000835 fiber Substances 0.000 description 8
- 230000000926 neurological effect Effects 0.000 description 8
- 230000000750 progressive effect Effects 0.000 description 8
- 230000000451 tissue damage Effects 0.000 description 8
- 231100000827 tissue damage Toxicity 0.000 description 8
- 208000003174 Brain Neoplasms Diseases 0.000 description 7
- 208000006011 Stroke Diseases 0.000 description 7
- 230000002411 adverse Effects 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 208000029560 autism spectrum disease Diseases 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 7
- 239000013626 chemical specie Substances 0.000 description 7
- 230000006999 cognitive decline Effects 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 230000001010 compromised effect Effects 0.000 description 7
- 238000013399 early diagnosis Methods 0.000 description 7
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 7
- 210000004884 grey matter Anatomy 0.000 description 7
- 208000019622 heart disease Diseases 0.000 description 7
- 230000007774 longterm Effects 0.000 description 7
- 210000004088 microvessel Anatomy 0.000 description 7
- 210000004165 myocardium Anatomy 0.000 description 7
- 208000020084 Bone disease Diseases 0.000 description 6
- 206010028594 Myocardial fibrosis Diseases 0.000 description 6
- 208000001132 Osteoporosis Diseases 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 230000000996 additive effect Effects 0.000 description 6
- 230000032683 aging Effects 0.000 description 6
- 239000012472 biological sample Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000000747 cardiac effect Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 210000000478 neocortex Anatomy 0.000 description 6
- 210000005036 nerve Anatomy 0.000 description 6
- 231100000915 pathological change Toxicity 0.000 description 6
- 230000036285 pathological change Effects 0.000 description 6
- 238000002600 positron emission tomography Methods 0.000 description 6
- 230000005751 tumor progression Effects 0.000 description 6
- 206010003694 Atrophy Diseases 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 208000030886 Traumatic Brain injury Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 230000037444 atrophy Effects 0.000 description 5
- 210000003050 axon Anatomy 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000003727 cerebral blood flow Effects 0.000 description 5
- 210000003618 cortical neuron Anatomy 0.000 description 5
- 238000002405 diagnostic procedure Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 238000011835 investigation Methods 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 210000005228 liver tissue Anatomy 0.000 description 5
- 230000002107 myocardial effect Effects 0.000 description 5
- 238000005457 optimization Methods 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 238000004393 prognosis Methods 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000035882 stress Effects 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 230000009529 traumatic brain injury Effects 0.000 description 5
- 238000002604 ultrasonography Methods 0.000 description 5
- ZCXUVYAZINUVJD-AHXZWLDOSA-N 2-deoxy-2-((18)F)fluoro-alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O ZCXUVYAZINUVJD-AHXZWLDOSA-N 0.000 description 4
- 206010061728 Bone lesion Diseases 0.000 description 4
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 description 4
- 208000018737 Parkinson disease Diseases 0.000 description 4
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 4
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 230000007792 alzheimer disease pathology Effects 0.000 description 4
- 230000002491 angiogenic effect Effects 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 238000005311 autocorrelation function Methods 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 208000017004 dementia pugilistica Diseases 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 239000005337 ground glass Substances 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 230000000971 hippocampal effect Effects 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 238000002075 inversion recovery Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 238000010603 microCT Methods 0.000 description 4
- 208000027061 mild cognitive impairment Diseases 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 230000001613 neoplastic effect Effects 0.000 description 4
- 230000001009 osteoporotic effect Effects 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 208000017497 prostate disease Diseases 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- 201000000980 schizophrenia Diseases 0.000 description 4
- 238000004904 shortening Methods 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 238000010408 sweeping Methods 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 238000012800 visualization Methods 0.000 description 4
- 208000024806 Brain atrophy Diseases 0.000 description 3
- 208000014644 Brain disease Diseases 0.000 description 3
- 201000003883 Cystic fibrosis Diseases 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 206010028347 Muscle twitching Diseases 0.000 description 3
- 206010061309 Neoplasm progression Diseases 0.000 description 3
- 238000012879 PET imaging Methods 0.000 description 3
- 238000002441 X-ray diffraction Methods 0.000 description 3
- 230000035508 accumulation Effects 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 210000004712 air sac Anatomy 0.000 description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 230000007882 cirrhosis Effects 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 210000005257 cortical tissue Anatomy 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000004868 gas analysis Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000004153 glucose metabolism Effects 0.000 description 3
- 230000004217 heart function Effects 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 230000001423 neocortical effect Effects 0.000 description 3
- 230000007171 neuropathology Effects 0.000 description 3
- 230000009022 nonlinear effect Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 208000005069 pulmonary fibrosis Diseases 0.000 description 3
- 230000000541 pulsatile effect Effects 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 230000003252 repetitive effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 230000007480 spreading Effects 0.000 description 3
- 238000003892 spreading Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 230000006459 vascular development Effects 0.000 description 3
- 238000010176 18-FDG-positron emission tomography Methods 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 230000005653 Brownian motion process Effects 0.000 description 2
- 208000027647 Cerebral Cortical Thinning Diseases 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 241000264877 Hippospongia communis Species 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 208000029523 Interstitial Lung disease Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010065973 Iron Overload Diseases 0.000 description 2
- 208000032382 Ischaemic stroke Diseases 0.000 description 2
- 208000009829 Lewy Body Disease Diseases 0.000 description 2
- 201000002832 Lewy body dementia Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- OTCCIMWXFLJLIA-UHFFFAOYSA-N N-acetyl-DL-aspartic acid Natural products CC(=O)NC(C(O)=O)CC(O)=O OTCCIMWXFLJLIA-UHFFFAOYSA-N 0.000 description 2
- OTCCIMWXFLJLIA-BYPYZUCNSA-N N-acetyl-L-aspartic acid Chemical compound CC(=O)N[C@H](C(O)=O)CC(O)=O OTCCIMWXFLJLIA-BYPYZUCNSA-N 0.000 description 2
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 2
- 208000037048 Prodromal Symptoms Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000003679 aging effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 208000029162 bladder disease Diseases 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 238000007470 bone biopsy Methods 0.000 description 2
- 230000037182 bone density Effects 0.000 description 2
- 230000037118 bone strength Effects 0.000 description 2
- 238000005537 brownian motion Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 230000000739 chaotic effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 230000001427 coherent effect Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- 238000013480 data collection Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000012631 diagnostic technique Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 238000002599 functional magnetic resonance imaging Methods 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000005865 ionizing radiation Effects 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000012317 liver biopsy Methods 0.000 description 2
- 238000007449 liver function test Methods 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 230000004199 lung function Effects 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 201000006938 muscular dystrophy Diseases 0.000 description 2
- 206010028537 myelofibrosis Diseases 0.000 description 2
- 238000013188 needle biopsy Methods 0.000 description 2
- 238000002610 neuroimaging Methods 0.000 description 2
- 239000000101 novel biomarker Substances 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000036314 physical performance Effects 0.000 description 2
- 208000007232 portal hypertension Diseases 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000009613 pulmonary function test Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000011435 rock Substances 0.000 description 2
- 230000002784 sclerotic effect Effects 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 230000011218 segmentation Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 238000000264 spin echo pulse sequence Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 230000008354 tissue degradation Effects 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- 208000026533 urinary bladder disease Diseases 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 208000037663 Best vitelliform macular dystrophy Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 206010006322 Breath holding Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 206010051290 Central nervous system lesion Diseases 0.000 description 1
- 206010008096 Cerebral atrophy Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 208000006154 Chronic hepatitis C Diseases 0.000 description 1
- 206010071068 Clinically isolated syndrome Diseases 0.000 description 1
- 208000031124 Dementia Alzheimer type Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 208000008924 Femoral Fractures Diseases 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 206010018341 Gliosis Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 206010019669 Hepatic fibrosis and cirrhosis Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 206010048654 Muscle fibrosis Diseases 0.000 description 1
- 238000012565 NMR experiment Methods 0.000 description 1
- 208000011623 Obstructive Lung disease Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000034038 Pathologic Neovascularization Diseases 0.000 description 1
- 206010054827 Peritoneal lesion Diseases 0.000 description 1
- 206010072360 Peritumoural oedema Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010056342 Pulmonary mass Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000016247 Soft tissue disease Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 238000012338 Therapeutic targeting Methods 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010072731 White matter lesion Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 210000003926 auditory cortex Anatomy 0.000 description 1
- 230000007844 axonal damage Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000003557 bones of lower extremity Anatomy 0.000 description 1
- 238000002725 brachytherapy Methods 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000001054 cardiac fibroblast Anatomy 0.000 description 1
- 238000013184 cardiac magnetic resonance imaging Methods 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000007374 clinical diagnostic method Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 238000005314 correlation function Methods 0.000 description 1
- 230000007591 cortical connectivity Effects 0.000 description 1
- 230000009509 cortical damage Effects 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 238000002681 cryosurgery Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000012517 data analytics Methods 0.000 description 1
- 238000013135 deep learning Methods 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000007435 diagnostic evaluation Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 206010013932 dyslexia Diseases 0.000 description 1
- 238000002091 elastography Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 208000020089 femoral neck fracture Diseases 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000005153 frontal cortex Anatomy 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 230000007387 gliosis Effects 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 238000012623 in vivo measurement Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000012804 iterative process Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011528 liquid biopsy Methods 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000007620 mathematical function Methods 0.000 description 1
- 238000012067 mathematical method Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000003007 myelin sheath Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 230000024121 nodulation Effects 0.000 description 1
- 230000003121 nonmonotonic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 238000004223 overdiagnosis Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000008529 pathological progression Effects 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000002360 prefrontal effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- 210000002763 pyramidal cell Anatomy 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000001454 recorded image Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000000679 relaxometry Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000005654 stationary process Effects 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
- 230000006438 vascular health Effects 0.000 description 1
- 230000006439 vascular pathology Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000004862 vasculogenesis Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 201000007790 vitelliform macular dystrophy Diseases 0.000 description 1
- 208000020938 vitelliform macular dystrophy 2 Diseases 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/48—NMR imaging systems
- G01R33/4818—MR characterised by data acquisition along a specific k-space trajectory or by the temporal order of k-space coverage, e.g. centric or segmented coverage of k-space
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/48—NMR imaging systems
- G01R33/483—NMR imaging systems with selection of signals or spectra from particular regions of the volume, e.g. in vivo spectroscopy
- G01R33/4833—NMR imaging systems with selection of signals or spectra from particular regions of the volume, e.g. in vivo spectroscopy using spatially selective excitation of the volume of interest, e.g. selecting non-orthogonal or inclined slices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4842—Monitoring progression or stage of a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/48—NMR imaging systems
- G01R33/4818—MR characterised by data acquisition along a specific k-space trajectory or by the temporal order of k-space coverage, e.g. centric or segmented coverage of k-space
- G01R33/482—MR characterised by data acquisition along a specific k-space trajectory or by the temporal order of k-space coverage, e.g. centric or segmented coverage of k-space using a Cartesian trajectory
- G01R33/4822—MR characterised by data acquisition along a specific k-space trajectory or by the temporal order of k-space coverage, e.g. centric or segmented coverage of k-space using a Cartesian trajectory in three dimensions
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/48—NMR imaging systems
- G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
- G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
- G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/48—NMR imaging systems
- G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
- G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
- G01R33/5602—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution by filtering or weighting based on different relaxation times within the sample, e.g. T1 weighting using an inversion pulse
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/48—NMR imaging systems
- G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
- G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
- G01R33/5605—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution by transferring coherence or polarization from a spin species to another, e.g. creating magnetization transfer contrast [MTC], polarization transfer using nuclear Overhauser enhancement [NOE]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/48—NMR imaging systems
- G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
- G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
- G01R33/561—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution by reduction of the scanning time, i.e. fast acquiring systems, e.g. using echo-planar pulse sequences
- G01R33/5615—Echo train techniques involving acquiring plural, differently encoded, echo signals after one RF excitation, e.g. using gradient refocusing in echo planar imaging [EPI], RF refocusing in rapid acquisition with relaxation enhancement [RARE] or using both RF and gradient refocusing in gradient and spin echo imaging [GRASE]
- G01R33/5617—Echo train techniques involving acquiring plural, differently encoded, echo signals after one RF excitation, e.g. using gradient refocusing in echo planar imaging [EPI], RF refocusing in rapid acquisition with relaxation enhancement [RARE] or using both RF and gradient refocusing in gradient and spin echo imaging [GRASE] using RF refocusing, e.g. RARE
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/48—NMR imaging systems
- G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
- G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
- G01R33/563—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution of moving material, e.g. flow contrast angiography
- G01R33/56341—Diffusion imaging
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- High Energy & Nuclear Physics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- General Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Optics & Photonics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/604,465 US10061003B2 (en) | 2014-09-01 | 2017-05-24 | Selective sampling for assessing structural spatial frequencies with specific contrast mechanisms |
| US15/604,465 | 2017-05-24 | ||
| PCT/US2018/033727 WO2018217658A1 (en) | 2017-05-24 | 2018-05-21 | Selective sampling for assessing structural spatial frequencies with specific contrast mechanisms |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020520786A JP2020520786A (ja) | 2020-07-16 |
| JP2020520786A5 JP2020520786A5 (enExample) | 2021-07-26 |
| JP7273803B2 true JP7273803B2 (ja) | 2023-05-15 |
Family
ID=64396914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020516380A Active JP7273803B2 (ja) | 2017-05-24 | 2018-05-21 | 特定のコントラスト機構を用いて構造的空間周波数を評価するための選択的サンプリング |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP3629915A4 (enExample) |
| JP (1) | JP7273803B2 (enExample) |
| CN (1) | CN110958854A (enExample) |
| AU (1) | AU2018273362A1 (enExample) |
| CA (1) | CA3064736A1 (enExample) |
| WO (1) | WO2018217658A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111803068A (zh) * | 2020-08-21 | 2020-10-23 | 上海中医药大学附属曙光医院 | 一种基于虚拟磁共振弹性成像的无创评估肝纤维化的方法 |
| CN113156350B (zh) * | 2021-03-25 | 2022-07-19 | 华南理工大学 | 无创光不透明微米级活体组织磁共振断层成像方法及系统 |
| US20230036757A1 (en) * | 2021-07-28 | 2023-02-02 | Ischemaview, Inc. | Concurrent display of hemodynamic parameters and damaged brain tissue |
| CN114371232B (zh) * | 2021-12-22 | 2024-03-22 | 天津国科医工科技发展有限公司 | 基于卡尔曼滤波算法的色谱滤波方法、装置、介质、系统 |
| CN116959586B (zh) * | 2022-04-18 | 2025-11-28 | 深圳华大生命科学研究院 | 空间组学数据的处理方法、电子设备及介质 |
| CN114936519B (zh) * | 2022-05-12 | 2025-09-05 | 中国人民解放军国防科技大学 | 一种可控模式光滤波器及优化方法 |
| CN114708973B (zh) * | 2022-06-06 | 2022-09-13 | 首都医科大学附属北京友谊医院 | 一种用于对人体健康进行评估的设备和存储介质 |
| CN116934757B (zh) * | 2023-09-18 | 2023-11-21 | 电子科技大学 | 一种用于肺结节假阳性删减的方法、设备及存储介质 |
| CN117388672B (zh) * | 2023-12-11 | 2024-04-19 | 四川睿杰鑫电子股份有限公司 | 一种电路板用电源通路检测装置及其检测方法 |
| CN119864176A (zh) * | 2024-12-26 | 2025-04-22 | 济南市人民医院 | 一种基于大数据的危重患者死亡风险预测方法 |
| CN119850613B (zh) * | 2025-03-19 | 2025-07-01 | 江苏省血吸虫病防治研究所 | 基于深度学习的血吸虫病可疑病灶区域标定系统 |
| CN120217588B (zh) * | 2025-03-24 | 2025-11-18 | 广东海思智能装备有限公司 | 一种数控机床主轴振动实时监测与自动抑制方法 |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001340314A (ja) | 2000-05-31 | 2001-12-11 | Hitachi Medical Corp | 磁気共鳴イメージング装置 |
| JP2005296663A (ja) | 2004-04-13 | 2005-10-27 | Siemens Ag | 磁気共鳴断層撮影の拡散強調画像のためのマルチショット方法 |
| JP2007502676A (ja) | 2003-08-21 | 2007-02-15 | アイシェム コーポレイション | 血管プラーク検出および分析のための自動化方法およびシステム |
| JP2008017925A (ja) | 2006-07-11 | 2008-01-31 | Hitachi Medical Corp | 核磁気共鳴撮像装置 |
| JP2010503503A (ja) | 2006-09-19 | 2010-02-04 | ノルディック・バイオサイエンス・イメージング・アクティーゼルスカブ | 軟骨構造に関連した病変表示測度及びその自動数量化 |
| JP2011177209A (ja) | 2010-02-26 | 2011-09-15 | Ge Medical Systems Global Technology Co Llc | 磁気共鳴イメージング装置 |
| JP2014204802A (ja) | 2013-04-11 | 2014-10-30 | ジーイー・メディカル・システムズ・グローバル・テクノロジー・カンパニー・エルエルシー | 磁気共鳴装置およびプログラム |
| JP2017023553A (ja) | 2015-07-24 | 2017-02-02 | ジーイー・メディカル・システムズ・グローバル・テクノロジー・カンパニー・エルエルシー | 磁気共鳴装置 |
| WO2017062882A1 (en) | 2015-10-07 | 2017-04-13 | bioProtonics LLC | Selective sampling for assessing structural spatial frequencies with specific contrast mechanisms |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3393895B2 (ja) * | 1993-09-13 | 2003-04-07 | 株式会社東芝 | 磁気共鳴映像装置 |
| US6320380B1 (en) * | 2000-10-03 | 2001-11-20 | Marconi Medical Systems, Inc. | MRI method and apparatus for increasing the efficiency of echo lanar imaging and other late echo techniques |
| US8057408B2 (en) * | 2005-09-22 | 2011-11-15 | The Regents Of The University Of Michigan | Pulsed cavitational ultrasound therapy |
| KR101297143B1 (ko) * | 2005-11-27 | 2013-08-21 | 아쿠이타스 메디컬 리미티드 | 공간 주파수 분석을 이용한 뼈와 같은 구조의 평가 |
| US20100145185A1 (en) * | 2008-12-04 | 2010-06-10 | Xiaole Hong | Extending the resolution of mri data by combining subsets from plural image acquisitions |
| JP5360757B2 (ja) * | 2009-04-22 | 2013-12-04 | 独立行政法人情報通信研究機構 | 磁気共鳴画像法および磁気共鳴画像装置 |
| US8966701B2 (en) * | 2012-06-14 | 2015-03-03 | Joseph Dellecave | Sole wipe |
| WO2014130813A1 (en) * | 2013-02-21 | 2014-08-28 | New York University | Method and device for accurate quantification of t2 relaxation times based on fast multi spin-echo nmr sequences |
| US9366740B2 (en) * | 2013-03-14 | 2016-06-14 | Wisconsin Alumni Research Foundation | System and method for vastly undersampled isotropic projection reconstruction with inversion recovery |
| US10386439B2 (en) * | 2013-12-20 | 2019-08-20 | Koninklike Philips N.V. | Density guided attenuation map generation in PET/MR systems |
| US9664760B2 (en) | 2014-09-01 | 2017-05-30 | bioProtonics, L.L.C | Selective sampling for assessing structural spatial frequencies with specific contrast mechanisms |
| CA2959621A1 (en) * | 2014-09-01 | 2016-03-10 | bioProtonics LLC | Selective sampling magnetic resonance-based method for assessing structural spatial frequencies |
| US9664759B2 (en) * | 2014-09-01 | 2017-05-30 | bioProtonics, L.L.C | Method for assessing structural spatial frequencies using hybrid sampling with non-zero gradient for enhancement of selective sampling |
| US9655522B2 (en) * | 2014-10-10 | 2017-05-23 | Cedars-Sinai Medical Center | Method and system for “push-button” comprehensive cardiac MR examination using continuous self-gated 3D radial imaging |
-
2018
- 2018-05-21 CN CN201880049872.3A patent/CN110958854A/zh active Pending
- 2018-05-21 JP JP2020516380A patent/JP7273803B2/ja active Active
- 2018-05-21 CA CA3064736A patent/CA3064736A1/en active Pending
- 2018-05-21 AU AU2018273362A patent/AU2018273362A1/en not_active Abandoned
- 2018-05-21 EP EP18805648.5A patent/EP3629915A4/en not_active Withdrawn
- 2018-05-21 WO PCT/US2018/033727 patent/WO2018217658A1/en not_active Ceased
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001340314A (ja) | 2000-05-31 | 2001-12-11 | Hitachi Medical Corp | 磁気共鳴イメージング装置 |
| JP2007502676A (ja) | 2003-08-21 | 2007-02-15 | アイシェム コーポレイション | 血管プラーク検出および分析のための自動化方法およびシステム |
| JP2005296663A (ja) | 2004-04-13 | 2005-10-27 | Siemens Ag | 磁気共鳴断層撮影の拡散強調画像のためのマルチショット方法 |
| JP2008017925A (ja) | 2006-07-11 | 2008-01-31 | Hitachi Medical Corp | 核磁気共鳴撮像装置 |
| JP2010503503A (ja) | 2006-09-19 | 2010-02-04 | ノルディック・バイオサイエンス・イメージング・アクティーゼルスカブ | 軟骨構造に関連した病変表示測度及びその自動数量化 |
| JP2011177209A (ja) | 2010-02-26 | 2011-09-15 | Ge Medical Systems Global Technology Co Llc | 磁気共鳴イメージング装置 |
| JP2014204802A (ja) | 2013-04-11 | 2014-10-30 | ジーイー・メディカル・システムズ・グローバル・テクノロジー・カンパニー・エルエルシー | 磁気共鳴装置およびプログラム |
| JP2017023553A (ja) | 2015-07-24 | 2017-02-02 | ジーイー・メディカル・システムズ・グローバル・テクノロジー・カンパニー・エルエルシー | 磁気共鳴装置 |
| WO2017062882A1 (en) | 2015-10-07 | 2017-04-13 | bioProtonics LLC | Selective sampling for assessing structural spatial frequencies with specific contrast mechanisms |
| JP2018529474A (ja) | 2015-10-07 | 2018-10-11 | バイオプロトニクス リミテッド ライアビリティー カンパニーＢｉｏｐｒｏｔｏｎｉｃｓ Ｌｌｃ | 特定のコントラスト機構を用いて構造的空間周波数を評価するための選択的サンプリング |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3064736A1 (en) | 2018-11-29 |
| CN110958854A (zh) | 2020-04-03 |
| EP3629915A4 (en) | 2021-03-03 |
| EP3629915A1 (en) | 2020-04-08 |
| WO2018217658A1 (en) | 2018-11-29 |
| JP2020520786A (ja) | 2020-07-16 |
| AU2018273362A1 (en) | 2020-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11175363B2 (en) | Selective sampling for assessing structural spatial frequencies with specific contrast mechanisms | |
| JP7273803B2 (ja) | 特定のコントラスト機構を用いて構造的空間周波数を評価するための選択的サンプリング | |
| JP6906507B2 (ja) | 特定のコントラスト機構を用いて構造的空間周波数を評価するための選択的サンプリング | |
| US9664760B2 (en) | Selective sampling for assessing structural spatial frequencies with specific contrast mechanisms | |
| AU2021201998B2 (en) | Selective sampling magnetic resonance-based method for assessing structural spatial frequencies | |
| Deistung et al. | Overview of quantitative susceptibility mapping | |
| Enzinger et al. | Nonconventional MRI and microstructural cerebral changes in multiple sclerosis | |
| US9404986B2 (en) | Measuring biological tissue parameters using diffusion magnetic resonance imaging | |
| US11353533B2 (en) | Methods and devices for contrast agent magnetic resonance imaging | |
| US9664759B2 (en) | Method for assessing structural spatial frequencies using hybrid sampling with non-zero gradient for enhancement of selective sampling | |
| Noguerol et al. | Advanced diffusion MRI and biomarkers in the central nervous system: a new approach | |
| Li et al. | Multi‐parametric MRI for radiotherapy simulation | |
| Kwon et al. | High frequency conductivity decomposition by solving physically constraint underdetermined inverse problem in human brain | |
| Raju et al. | Transforming Medical Imaging with IVIM MR Imaging: A Comprehensive Review of Advances and Challenges in Perfusion and Diffusion Analysis | |
| Ellingson et al. | Novel spinal cord imaging | |
| Figini | Model-based analysis of diffusion Magnetic Resonance: study of microstructural damage in white matter and gray matter diseases | |
| Nagahara | Studies on Functional Magnetic Resonance Imaging with Higher Spatial and Temporal Resolutions | |
| Bian | MR PHASE AND SUSCEPTIBILITY-WEIGHTED IMAGING OF IRON DEPOSITION IN MULTIPLE SCLEROSIS AND RADIATION-TREATED BRAIN TUMORS | |
| Vallée et al. | Renal Fibrosis Assessment by Diffusion-Weighted Magnetic Resonance Imaging |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210520 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210520 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220318 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220419 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220719 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20221011 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230210 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20230210 |
|
| C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20230221 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20230306 |
|
| C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20230307 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230404 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230428 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7273803 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |